title: Postintervention duration of anticoagulation in venous surgery.
abstract: For a substantial proportion of patients with deep venous thrombosis (DVT), current treatment strategies are suboptimal and new treatment options are needed. Especially for the group of patients who are at the highest risk for post-thrombotic syndrome, new treatment modalities such as catheter-directed thrombolysis and additional stenting are being investigated. With current clinical studies addressing new technical options, the medical management of patients following these interventions deserves attention. The duration of anticoagulant treatment following surgical or radiological interventions for DVT seems not to be influenced by the presence of a venous stent. According to recent ACCP 2012 guidelines the anticoagulant management in patients who have had any method of thrombus removal performed, the same intensity and duration of anticoagulant therapy as in comparable patients who do not undergo thrombosis removal is recommended (Grade 1B). In the acute phase of thrombosis, irrespective of the technique and whether or not stenting is applied, immediate anticoagulation following the procedure is pertinent to reduce the risk of recurrent thrombosis and thrombus propagation. The long-term treatment duration after venous interventions therefore may be tailored based on common risk factors for recurrent thrombosis and the individual risk for bleeding. Selected thrombophilia factors, d-dimer assessment and residual venous thrombosis provide markers for recurrent DVT. Currently, vitamin K antagonists) provide the main anticoagulants for (prolonged) anticoagulation, while the new oral anticoagulants emerge as promising alternatives. In case prolonged anticoagulation after unprovoked DVT is not indicated, cardiovascular risk management is warranted because of an increased rate of arterial thrombotic events after DVT; aspirin may be indicated as secondary prevention against recurrent thrombosis (while providing primary prevention against arterial thrombosis).
authors.affiliation: Department of Internal Medicine, Cardiovascular Research Institute Maastricht (CARIM) and School for Public Health and Primary Care (Caphrie), Maastricht University Medical Centere, Maastricht, The Netherlands.
authors.forename: A J
authors.initials: AJ
authors.lastname: Ten Cate-Hoek
authors.forename: M H
authors.initials: MH
authors.lastname: Prins
authors.forename: C H A
authors.initials: CH
authors.lastname: Wittens
authors.forename: H
authors.initials: H
authors.lastname: ten Cate
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D054070:Postthrombotic Syndrome / Q000209:etiology / Q000517:prevention & control*; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000009:adverse effects / Q000295:instrumentation; D020246:Venous Thrombosis / Q000150:complications / Q000601:surgery*
chemical_list: D000925:Anticoagulants